Navigation Links
Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis
Date:1/28/2009

Golimumab Will Earn Decision Resources' Gold Standard for Rheumatoid Arthritis in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed rheumatologists say that a therapy's effect on reducing the signs and symptoms of rheumatoid arthritis at one year is the attribute that most influences their prescribing decisions in treating the disease. Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage in this attribute over Amgen/Wyeth/Takeda's Enbrel (etanercept), the market sales-leading agent.

The new report entitled Rheumatoid Arthritis: A Novel Oral Therapy Must Satisfy Physicians' High Expectations for Efficacy to Tap Significant Market Opportunity finds that an oral disease-modifying drug with a novel mechanism of action that is priced 20 percent lower than etanercept plus methotrexate would earn a 25 percent patient share in the United States and a 20 percent patient share in Europe, according to surveyed U.S. and European rheumatologists.

Decision Resources' proprietary clinical gold standard in 2008 for rheumatoid arthritis was Enbrel, most notably because of its superior efficacy in inhibiting/slowing structural damage progression at one and two years compared with other agents in the market. Following its approval for the indication, which is likely to occur in 2010, Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's Simponi (golimumab) will earn Decision Resources' gold standard for rheumatoid arthritis in 2012. Although Simponi's overall efficacy, safety and tolerability do not match that of Enbrel, its advantages in delivery differentiate it from Enbrel.

"Simponi ranks higher than Enbrel on the measures of dosage formulation and d
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
2. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
3. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
4. Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies
5. Experimental drug boosts survival in recurrent ovarian cancer
6. Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees
7. Stop eating for two: obese moms-to-be should gain less weight than currently recommended
8. Switching to MA Coverage Unlikely for Current Beneficiaries With MediGap or Medicare Only
9. The Current Recall of Boy Scouts of Americas Plastic Badges Does Not Affect Embroidered Insignia, Badges & Awards Produced by Lion Brothers Company Inc.
10. Purified Fish Oil Concentrates Offer Solution to Current Seafood Controversy for Pregnant and Breastfeeding Women!
11. ALEVE-D(R) Sinus & Cold Offers Option for the More Than 50% of Consumers Not Satisfied with Current Sinus Medication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... New York, NY (PRWEB) November 22, 2014 ... Australia’s Therapeutics Goods Administration (TGA) approved it for ... Glutathione was approved and listed within the Therapeutic ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione ... Chem, a biotech specialist that sources and imports ...
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 ... about the pain caused by the machine," said an ... injury, she had to go back a second time ... my invention idea." , She developed the patent-pending MAMO ... for breast cancer. The design saves the patient from ...
(Date:11/22/2014)... Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) that ... developed Type 2 diabetes due to its use continue ... underway in U.S. District Court, District of South Carolina, ... litigation will convene its next Status Conference on December ... Counsel for Plaintiffs and Defendants to meet and confer, ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 The Sports ... Roy Baroff to its team of conflict resolution ... soccer player, coach, and referee. He has over 30 years ... and beyond. , “I'm very excited to connect with SCI ... sports related interests to a program with a complete sports ...
(Date:11/22/2014)... 2014 Wright & Schulte LLC reports ... have been scheduled between October 2016 and April ... Illinois. U.S. District Judge Matthew F. Kennelly, who is ... Order (CMO) on November 6, 2014 that outlined the ... submit documents and other activities in preparation for the ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
... EMERYVILLE, Calif., March 13 Bionovo, Inc.,(Nasdaq: ... quarter and,full year ended December 31, 2007., Fourth ... three months ended December 31,2007 of $330,875 compared to ... revenues over the comparable period in 2006, is due ...
... Tool Uniquely Provides Minute-by-Minute and Trend Information That Can ... Lead to ... The Food and Drug,Administration (FDA) has approved the ... the United,States for people with diabetes. Designed to discretely ...
... of convertible notes due June 2008 ... net operating expenses going forward Projects ... SEATTLE, March 13 Seattle-Cell Therapeutics,Inc. (CTI) (Nasdaq: CTIC ... quarter and twelve months ended December 31,2007., Recent Events, ...
... Inc., leaders in light therapy, proudly receives its ... ... Photo Therapeutics, Inc. is,pleased to announce it has received FDA approval ... of,periorbital wrinkles., (Photo: http://www.newscom.com/cgi-bin/prnh/20080312/LAW011 ), Omnilux New-U has ...
... FACEP (E), Executive,Director, American Public Health Association, ... (EPA) today announced more protective National Ambient,Air Quality ... recognize,the new standards as a much needed improvement ... Public Health Association (APHA) is concerned that,the allowed ...
... in poor neighborhoods most likely to watch TVs or computers, ... new survey reports that teenagers spend far too many hours ... in poor neighborhoods have even more "screen time." , "The ... some of these kids don,t have healthier alternatives in their ...
Cached Medicine News:Health News:Bionovo Announces 2007 Financial Results and Highlights 2Health News:Bionovo Announces 2007 Financial Results and Highlights 3Health News:Bionovo Announces 2007 Financial Results and Highlights 4Health News:Bionovo Announces 2007 Financial Results and Highlights 5Health News:Bionovo Announces 2007 Financial Results and Highlights 6Health News:Bionovo Announces 2007 Financial Results and Highlights 7Health News:Bionovo Announces 2007 Financial Results and Highlights 8Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 2Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 3Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 4Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 5Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 2Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 3Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 4Health News:Omnilux New-U(TM) Hand-Held Device Receives FDA Approval 2Health News:APHA Says New Ozone Regulations a Missed Opportunity to Protect Public's Health 2Health News:Teens Spending Too Much Screen Time 2
(Date:11/21/2014)... Nov. 21, 2014  Alere Inc. (NYSE: ... has appointed Juliet Cunningham as Vice President, ... be responsible for driving communications with the investment community. ... series of changes to increase shareholder value, it is ... said Namal Nawana, Chief Executive Officer. "We are delighted ...
(Date:11/21/2014)...  Tandem Diabetes Care ® , Inc. (NASDAQ: ... and manufacturer of the t:slim ® Insulin ... non-profit dedicated to improving diabetes therapy management by ... diabetes data accessibility. This partnership will enable users ... development, to download and access data from their ...
(Date:11/21/2014)... 21, 2014  World Hemp Oil, an importer of ... they are now offering legal, organic oil with high ... strains grown in medical marijuana states. People suffering from ... as Parkinson,s, MS, and spinal cord injury, no longer ... because imported CBD Oil Is legal in all states. ...
Breaking Medicine Technology:Alere Appoints Juliet Cunningham to Lead Investor Relations 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3
... VOLC ), a leading developer and manufacturer of ... and treatment of coronary and peripheral vascular disease, today announced ... quarter of fiscal 2011 on Wednesday, May 4. ... financial results and operating activities open to all interested parties ...
... Inc. (Nasdaq: PDII ) today announced that ... to enable eDetail delivery on popular mobile devices including ... iPhone ® (1) and Android™(2)-based phones. "With ... than the general population, we are moving quickly to ...
Cached Medicine Technology:Volcano Corporation Schedules First Quarter Conference Call, Webcast 2PDI Announces Group DCA's Launch of eDetailing Across Apple® and Android™ Mobile Devices 2
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
Medicine Products: